Patients with BRCA 1/2 mutations not at increased risk for anthracycline-induced cardiotoxicity
the ONA take:
According to a new study presented last week at the 2014 San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, researchers from Georgetown Lombardi Comprehensive Cancer Center and MedStar Heart & Vascular Institute in Washington, D.C., have found that patients with BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity compared with women who do not have the gene mutations.
The study was prompted by findings of preclinical studies that suggested otherwise. For the study, researchers enrolled 81 patients, 39 of whom were BRCA 1/2 carriers and 42 did not have the mutation. Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and metastatic disease were not included in the study. Patients with a history of hypertension were excluded as well.
To determine cardiotoxicity, patients had an echocardiogram following anthracycline therapy to determine left ventricular ejection fraction (LVEF) and global longitudinal strain (GLS). Both are measurements to determine cardiac function.
Results showed that 91% of women had a normal LVEF and 85% had a normal GLS, which were measured on average 45 months after therapy. Only one patient with BRCA 1/2 mutation had borderline reduced LVEF.
BRCA 1/2 gene mutations do not have an increased risk of anthracycline-induced cardiac toxicity.
- Cholesterol-Lowering Drugs May Prevent Breast Cancer Recurrence
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia
- Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline
- Immunotherapy and the Future of Prostate Cancer Treatment
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Nut Consumption Inversely Associated With Lung Cancer Risk
- Use of Checkpoint Inhibitors in Urothelial Carcinoma
- Chemo + Radiotherapy Efficacious in Muscle-invasive Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Colorectal Cancer Risk Higher With Poor Metabolic Health vs Increased Weight
- Best Approach to Infection and Tumor Treatment: Contain or Eliminate?
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|